Alacrita

David works principally with small biotechs and start up companies, project managing late stage research projects through to first in man and Phase II trials.

He has over 20 years experience within the biotechnology industry, having started with Celltech following his postdoctoral research.

After 10 years with Celltech, David was Preclinical Development Director at Nicox, managing the development of a series of novel compounds based on conventional medicines.

From Nicox, he moved to lead the Project Management at KS Biomedix – later Xenova.

David has a track record of taking projects from research into first in man studies and has also assisted with successful partnering and mergers with Big Pharma.